Expression of p53 Protein Product in Triple Negative Breast Cancers and Relation with Clinical and Histopathological Parameters/ Експресија На Р53 Протеинскиот Продукт Кај Тројно Негативните Карциноми На Дојка Во Сооднос Со Клиничките И Хистопатолошките Параметри
Introduction: "Triple" negative breast cancer is a subgroup of so-called basal-like breast cancer. They are represented with 15% of all breast cancers, characterized with lack of hormone receptor as well as with negative expression of HER2 test. These tumors are more frequent in Afro-Americans and Latin-Americans, in patients with BRCA1 mutations and in patients with recent delivery. The aim of this study is to present the immunohistochemical and clinico-pathological characteristics of the triple negative breast cancer and their correlation with expression of the protein product of the tumor suppressor gene p53.
Methods: A retrospective analyses of 24 patients with triple negative breast cancer was performed. All of the patients were evaluated in the Histopathological Laboratory of the Clinical Hospital Sistina, during the period from June 2009, until June 2011. The standard immunohistochemical procedures, including the hormone receptor status, HER2 status, proliferative index - Ki67 and p53 gene protein product were performed, as well as additional immunohistochemical staining for socalled basal keratins (Cytokeratin 5/6 and high molecular weight cytokeratin 34BE12).
Results: The age of the patients ranged from 29-77 years. Positive lymph nodes were found in 14 (59%) patients. The tumor was poorly differentiated in 19 patients (79%). Overexpression of the p53 protein product was evaluated in 19 (79%) of the cases. All p53 negative patients (5/5) had poorly differentiated tumors (G3), associated with positive regional lymph nodes. The p53 positive group expressed quite opposite correlation, only 9/19 (47%) were with positive lymph nodes (p = 0.03). The expression of p53 protein product was also associated with the nuclear grade (p = 0.005), the mitotic index (p = 0.001), lymph-vascular invasion (p = 0.005) and with the proliferation index Ki67 (p = 0.003). There was a trend for association with the tumor size - pT (p = 0.05).
Conclusion: According to the results, the triple negative breast cancers are subgroup of the poorly differentiated neoplasms frequently associated in the younger age groups. The majority of these have overexpression of the p53 protein product, which in other hand, are inversely correlated with lymph nodes metastases. Hence, the necessity of enriching the immunohistochemical protocol of these patients with new antibodies, in order to evaluate their expression, which would be helpful for prediction the outcome of different therapeutical modalities.
1. Tavassoli FA. Pathology of the Breast, 2nd ed. Stamford, Connecticut; Appleton & Lange; 1999.
2. Moinfar F. ed. Essentials of Diagnostic Breast Pathology, Berlin: Heidelberg: Springer; 2007.
3 Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008; 107: 309-330.
4. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003; 21: 292-300.
5. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006; 13(2): 293-325.
6. Park D, Karesen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch. 2007; 451: 11-18.
7. De Azambuja E, Cardoso F, De Castro G, Colozzo M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart- Bebhart MJ, Paesmans M. Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12.155 patients. Br J Cancer. 2007; 96: 1504-1513.
8. Eden P, Ritz C, Rose C, Ferno M, Peterson C."Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004; 40: 1837-1841.
9. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003; 88: 1191-1198.
10. Pease AC, Solas D, Sullivan EJ, Cronin MT, C. Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci USA. 1994; 91: 5022-5026.
11. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270: 467-470.
12. Perou CM, Sorlie T, Eisen MB, van de Rijin M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikv A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D, Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
13. Sorlie T, Perou CM, Tibshiranin R, Aas T, Geisler S, Johnsen H, Hasti T, Eisen MB, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen- Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874.
14. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J,. Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA. 2006; 295(21): 2492-2502.
15. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28(10): 1684-1691.
16. Carey LA. Molecular intrinsic subtypes of breast cancer. In: UpToDate. Hayes DF, Dizon DS, eds. Waltham, MA: UpToDate; 2012. p. 77-84.
17. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70.
18. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, Colditz GA, Tamimi RM. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat. 2011; 126(1): 185-192.
19. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 2011; 29(29): 3885-3891.
20. Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea Ilies G, Bayakly AR, O'Regan RM, Vertino PM, Eley JW. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010; 116(11): 2549-2559.
21. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006; 25(43): 5846-5853.
22. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K,. Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109(1):123-139.
23. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Banchard RA, Lee JC, King TC, Rosenberg CL. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009; 11(2): R18.
24. Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: Implications for breast cancer screening recommendations. Cancer. 2011; 117(12): 2747-2753.
25. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008; 26(26): 4282-4288.
26. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretoy J, Theocharus C, Capp A, Nasser E, Kearsley JH, Delaney G, Papadatos G, Fox C, Sutherland RL. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009; 27(28): 4701-4708.
27. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006; 37(9): 1217-1226.
28. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 103(3): 250-263.
29. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012; 131(1): 159-167.
30. Rosai J. Rosai and Ackerman’s Surgical Pathology, 9th ed. London; Mosby; 2004.
31. American Joint Committee on Cancer - AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag; 2010.
32. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11 (3): 359-377.
33. Genestie C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, Vincent-Salomon A, Sastre-Garau, X. Comparison of the prognostic value of Scarff- Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems. Anticancer Res. 1998;18(1B): 571-576.
34. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.
35. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22(3): 207-219.
36. Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F. Nottingham prognostic index in triple negative breast cancer: a reliable prognostic tool? BMC Cancer. 2011; 11: 299-308.
37. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox BS, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt Sj, Scmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12: 207-219.
38. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO. Prognostic markers in triple negative breast cancer. Cancer. 2007; 109: 25-32.
39. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol. 2013; 66(6): 512-6.
40. Pathmanathan N, Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments. Pathology. 2012; 44(7): 587-95.
41. Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34bE12) is an independent predictor of disease-free survival in patients with triple-negative tumors of the breast. J Clin Pathol. 2010; 63: 744-747.
42. Gusterson B, Ross D, Heath V, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005; 7: 143-148. 43 Rakha EA, Reis-Filho JS, Ellis IO.Basal-like breast cancer: a critical review. J Clin Oncol. 2007; 26: 2568-2581.
44. Cheang M, Voduc D, Bajdik C, Leung S, Mckinney S, Chia SK. Вasal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin Cancer Res. 2008;14: 1368-1376.
45. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 7.1 2007: 134.
46. Salman MI, Elhefnawy NG, Shash LS. Morphological and immunohistochemical characteristics of triple negative and basal breast carcinoma. Egypt J Path. 2012; 32: 6-13.
47. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000; 88: 804-813.
48. Carter CL, Allen C, Henderson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181-187.
49. Korkolis DP, Tsoli E, Fouskakis D, Yiotis G, Koullias J, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are inde pendent prognostic factors in breast cancer patients. Anticancer Res. 2004; 24: 2061-2068.
50. Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep. 2005; 14: 337-343.
51. Nakagawa M, Bando Y, Nagao T, Morimoto M, Takai C, Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Sasa M, Tangoku A. Expression of p53, Ki67, E-cadherin, N-cadherin and Topoisomerase 2A (TOP-2A) in triple negative breast cancer. Anticancer Res. 2011; 31: 2389-2393.
52. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, Hammel N, Goffin JR, Wong N, Trudel M, Kapusta L Porter P, Akslen LA. Advances in brief the prognostic implication of the basal-like phenotype of BRCA1-related breast cancer (cyclin/high/p27low/p53/glomeruloid-microvascularproliferation). Cancer Res. 2004; 64: 830-835.
53. Lerma E, Peiro G, Ramon T, Fernandez S, Martinez D, Pons C, Munoz F, Sabate JM, Alonso C, Ojeda B, Prat J, Barnadas A. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basallike breast carcinomas). Mod Pathol. 2007; 20: 1200-1207.
54. Kreike B, van Kouwenhove M, Horlings H,Weigelt B, Peterse H, Bartelink H, van der Vijver M. Gene expression profiling and histopathological characterization of triple- negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9: R65.
55. Bhargava R, Striebel J, Beriwal S, Flickinger JC, Onisko A, Ahrendt G, Dabbs DJ. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int Ј Clin Exp Pathol. 2009; 2: 444-455.
56. Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, Hoogerbrugge N, van Leeuwen I, Vasen HF, Cleton-Jansen AM, Kraan J, Houwing- Duistermaat JJ, Morreau H, Cornelisse CJ, Devilee P. Characterization of familial non-BRCA1/2 breast tumours by loss of heterozygosity and immunophenotyping. Clin Cancer Res. 2006; 12: 1693-1700.